Key Points

  • Anti-ADAMTS13 autoantibodies from iTTP patients induce an open ADAMTS13 conformation.

  • An open ADAMTS13 conformation is a novel and sensitive biomarker for subclinical iTTP.

Abstract

Recently, we showed that ADAMTS13 circulates in an open conformation during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP). Although the cause of this conformational change remains elusive, ADAMTS13 is primarily closed in iTTP patients in remission with ADAMTS13 activity >50% and undetectable anti-ADAMTS13 autoantibodies, as well as after rituximab treatment, suggesting a role for anti-ADAMTS13 autoantibodies. Therefore, immunoglobulin G from 18 acute iTTP patients was purified and added to closed ADAMTS13 in healthy donor plasma. This resulted in open ADAMTS13 in 14 of 18 (78%) samples, proving that anti-ADAMTS13 autoantibodies can induce an open ADAMTS13 conformation. To further elucidate the conformation of ADAMTS13 in iTTP patients, we studied a novel iTTP patient cohort (n = 197) that also included plasma samples from iTTP patients in remission in whom ADAMTS13 activity was <50%. The open ADAMTS13 conformation was found during acute iTTP, as well as in patients in remission with ADAMTS13 activity <50% and in half of the patients with ADAMTS13 activity >50%, although free anti-ADAMTS13 autoantibodies were not always detected. Thus, open ADAMTS13 is a hallmark of acute iTTP, as well as a novel biomarker that can be used to detect subclinical iTTP in patients in remission. Finally, a long-term follow-up study in 1 iTTP patient showed that the open conformation precedes a substantial drop in ADAMTS13 activity. In conclusion, we have shown that anti-ADAMTS13 autoantibodies from iTTP patients induce an open ADAMTS13 conformation. Most importantly, an open ADAMTS13 conformation is a biomarker for subclinical iTTP and could become an important tool in TTP management.

REFERENCES

REFERENCES
1.
Furlan
M
,
Robles
R
,
Galbusera
M
, et al
.
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
.
N Engl J Med
.
1998
;
339
(
22
):
1578
-
1584
.
2.
Tsai
H-M
,
Lian
EC
.
Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
.
N Engl J Med
.
1998
;
339
(
22
):
1585
-
1594
.
3.
Scheiflinger
F
,
Knöbl
P
,
Trattner
B
, et al
.
Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura
.
Blood
.
2003
;
102
(
9
):
3241
-
3243
.
4.
Rieger
M
,
Mannucci
PM
,
Kremer Hovinga
JA
, et al
.
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases
.
Blood
.
2005
;
106
(
4
):
1262
-
1267
.
5.
Feys
HB
,
Liu
F
,
Dong
N
, et al
.
ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences
.
J Thromb Haemost
.
2006
;
4
(
5
):
955
-
962
.
6.
Joly
BS
,
Coppo
P
,
Veyradier
A
.
Thrombotic thrombocytopenic purpura
.
Blood
.
2017
;
129
(
21
):
2836
-
2846
.
7.
Kremer Hovinga
JA
,
Coppo
P
,
Lämmle
B
,
Moake
JL
,
Miyata
T
,
Vanhoorelbeke
K
.
Thrombotic thrombocytopenic purpura
.
Nat Rev Dis Primers
.
2017
;
3
(
1
):
17020
.
8.
Tersteeg
C
,
Fijnheer
R
,
Pasterkamp
G
, et al
.
Keeping von Willebrand factor under control: alternatives for ADAMTS13
.
Semin Thromb Hemost
.
2016
;
42
(
1
):
9
-
17
.
9.
Zheng
X
,
Chung
D
,
Takayama
TK
,
Majerus
EM
,
Sadler
JE
,
Fujikawa
K
.
Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura
.
J Biol Chem
.
2001
;
276
(
44
):
41059
-
41063
.
10.
Muia
J
,
Zhu
J
,
Gupta
G
, et al
.
Allosteric activation of ADAMTS13 by von Willebrand factor
.
Proc Natl Acad Sci USA
.
2014
;
111
(
52
):
18584
-
18589
.
11.
South
K
,
Luken
BM
,
Crawley
JTB
, et al
.
Conformational activation of ADAMTS13
.
Proc Natl Acad Sci USA
.
2014
;
111
(
52
):
18578
-
18583
.
12.
South
K
,
Freitas
MO
,
Lane
DA
.
A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor [published correction appears in J Biol Chem. 2018;203(4):1149-1150]
.
J Biol Chem
.
2017
;
292
(
14
):
5760
-
5769
.
13.
Deforche
L
,
Roose
E
,
Vandenbulcke
A
, et al
.
Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13
.
J Thromb Haemost
.
2015
;
13
(
11
):
2063
-
2075
.
14.
Roose
E
,
Schelpe
A-S
,
Joly
BS
, et al
.
An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2018
;
16
(
2
):
378
-
388
.
15.
Jestin
M
,
Benhamou
Y
,
Schelpe
AS
, et al;
French Thrombotic Microangiopathies Reference Center
.
Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura
.
Blood
.
2018
;
132
(
20
):
2143
-
2153
.
16.
Jin
M
,
Casper
TC
,
Cataland
SR
, et al
.
Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse
.
Br J Haematol
.
2008
;
141
(
5
):
651
-
658
.
17.
Peyvandi
F
,
Lavoretano
S
,
Palla
R
, et al
.
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission
.
Haematologica
.
2008
;
93
(
2
):
232
-
239
.
18.
Starke
R
,
Machin
S
,
Scully
M
,
Purdy
G
,
Mackie
I
.
The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura
.
Br J Haematol
.
2007
;
136
(
4
):
649
-
655
.
19.
Westwood
JP
,
Thomas
M
,
Alwan
F
, et al
.
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens
.
Blood Adv
.
2017
;
1
(
15
):
1159
-
1166
.
20.
Mai Falk
J
,
Scharrer
I
.
Idiopathic thrombotic thrombocytopenic purpura: strongest risk factor for relapse from remission is having had a relapse
.
Transfusion
.
2016
;
56
(
11
):
2819
-
2823
.
21.
Ferrari
S
,
Scheiflinger
F
,
Rieger
M
, et al;
French Clinical and Biological Network on Adult Thrombotic Microangiopathies
.
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity
.
Blood
.
2007
;
109
(
7
):
2815
-
2822
.
22.
Kremer Hovinga
JA
,
Vesely
SK
,
Terrell
DR
,
Lämmle
B
,
George
JN
.
Survival and relapse in patients with thrombotic thrombocytopenic purpura
.
Blood
.
2010
;
115
(
8
):
1500
-
1511, quiz 1662
.
23.
Bettoni
G
,
Palla
R
,
Valsecchi
C
, et al
.
ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2012
;
10
(
8
):
1556
-
1565
.
24.
Page
EE
,
Kremer Hovinga
JA
,
Terrell
DR
,
Vesely
SK
,
George
JN
.
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura
.
Blood
.
2016
;
128
(
17
):
2175
-
2178
.
25.
Hie
M
,
Gay
J
,
Galicier
L
, et al;
French Thrombotic Microangiopathies Reference Centre
.
Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura
.
Blood
.
2014
;
124
(
2
):
204
-
210
.
26.
Westwood
JP
,
Webster
H
,
McGuckin
S
,
McDonald
V
,
Machin
SJ
,
Scully
M
.
Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse
.
J Thromb Haemost
.
2013
;
11
(
3
):
481
-
490
.
27.
Scully
M
,
Cataland
S
,
Coppo
P
, et al;
International Working Group for Thrombotic Thrombocytopenic Purpura
.
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies
.
J Thromb Haemost
.
2017
;
15
(
2
):
312
-
322
.
28.
Kokame
K
,
Nobe
Y
,
Kokubo
Y
,
Okayama
A
,
Miyata
T
.
FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay
.
Br J Haematol
.
2005
;
129
(
1
):
93
-
100
.
29.
Froehlich-Zahnd
R
,
George
JN
,
Vesely
SK
, et al
.
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura
.
Haematologica
.
2012
;
97
(
2
):
297
-
303
.
30.
Ferrari
S
,
Mudde
GC
,
Rieger
M
,
Veyradier
A
,
Kremer Hovinga
JA
,
Scheiflinger
F
.
IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2009
;
7
(
10
):
1703
-
1710
.
31.
McDonald
V
,
Liesner
R
,
Grainger
J
,
Gattens
M
,
Machin
SJ
,
Scully
M
.
Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays
.
Blood Coagul Fibrinolysis
.
2010
;
21
(
3
):
245
-
250
.
32.
Falter
T
,
Herold
S
,
Weyer-Elberich
V
, et al
.
Relapse rate in survivors of acute autoimmune thrombotic thrombocytopenic purpura treated with or without rituximab
.
Thromb Haemost
.
2018
;
118
(
10
):
1743
-
1751
.
33.
Sun
L
,
Mack
J
,
Li
A
, et al
.
Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura
.
Blood Adv
.
2019
;
3
(
9
):
1512
-
1518
.
34.
Mancini
I
,
Ferrari
B
,
Valsecchi
C
, et al;
Italian Group of TTP Investigators
.
ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura
.
Eur J Intern Med
.
2017
;
39
:
79
-
83
.
35.
Lotta
LA
,
Valsecchi
C
,
Pontiggia
S
, et al
.
Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura
.
J Thromb Haemost
.
2014
;
12
(
3
):
329
-
336
.
36.
Hrdinová
J
,
D’Angelo
S
,
Graça
NAG
, et al
.
Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers
.
Haematologica
.
2018
;
103
(
7
):
1099
-
1109
.
37.
Schelpe
A-S
,
Roose
E
,
Joly
BS
, et al
.
Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients
.
Haematologica
.
2019
;
104
(
6
):
1268
-
1276
.
You do not currently have access to this content.